Cystic Fibroids
Cystic fibrosis
Cystic fibrosis is a disease that can be passed down from one generation to the other. It affects secretary glands that produce mucus and sweat. The disease results after the fibrosis transmembrane conductance regulator (CFTR) gene that is found on chromosome 7 has undergone some sort of mutation. Mutation on chromosome 7 alters the production and function of CFTR glycoprotein (Scott, 2013). Studies have identified more than 1600 variations of CFTR mutations. Significant numbers of cystic fibrosis patients have amino acid 508 defects. The amino acid 508 mutation basically occurs when CFTR protein is missing 3 base pairs at position 508 on CFTR protein sequence which codes for phenylalanine. Phenylalanine is essential in nutrition. There are other mutations that mainly occur in non-white populations (Scott, 2013). The CFTR mutations interfere with how sodium and chloride is transported on the apical surface level of exocrine gland epithelial cells. Cystic fibrosis presents in the epithelial cells of patient's respiratory avenues, sweat glands, gastrointestinal tracts, and genitourinary systems. This causes dehydration and production of thick secretions in a number of organs. Lungs, sinuses, pancreas, intestines, hepatobiliary tree, and vas deferens are mostly affected. Nearly 5% of the entire United States population has defective CFTR gene (Scott, 2013). Worse still a bigger portion of the population are still asymptomatic carriers. This is some news that the healthcare service providers and the larger community should be worried about. Bearing in mind that this is a genetic disorder and that the number of asymptomatic carriers have not been accounted for it can as well be that over half of the United States population carries this defective gene that causes cystic fibrosis (Scott, 2013). The fact that the disease presents in epithelial cells of patient's airways should be a worry to the healthcare practitioners. Thick secretions that are resultantly produced in the lungs are likely to interfere with patient's respiratory system which can be fatal if not mitigated in good time. This should not be any form of news to us because we all clearly know that the lungs facilitate uptake of oxygen that is pivotal in energy transduction process and the removal of gases that are produced in the process of energy production that cannot be used by the human system (Scott, 2013).
Diagnosis
Cystic fibrosis can be diagnosed using biochemical or genetic testing avenues. Phenotypic features like gastrointestinal and nutritional abnormalities, salt-loss syndrome, and male urogenital abnormalities could be an indication that a person is suffering cystic fibrosis (Scott, 2013). When a new borne baby suffers from intestinal obstruction where stool gets stuck in the bowel, this could be one of the earliest manifestations of the disease. Twenty percent of infants with cystic fibrosis develop this kind of obstruction. Patients with cystic fibrosis also experience chronic cough, frequent and foul smelling stools, and persistent upper respiratory infections (Starner & McCray, 2005). This could be some early indication that somebody is suffering from cystic fibrosis. They may also exhibit electrolyte imbalance, nasal polyps and sinus disease, rectal prolapse, and reproductive complications. Adults with cystic fibrosis tend to live longer and therefore develop non-respiratory symptoms. Children with cystic fibrosis are diagnosed by the age of one year. Coughing is predominant in early stages of this disease. Children with ages below ten months experience chronic coughing.
A number of tests can be performed when cystic fibrosis is suspected. Such tests include prenatal genetic testing, ultrasonography, and amniocentesis. The most frequently used test is a sweat chloride test. The test is facilitated by stimulating the sweat glands of the patient's forearm or thigh with pilocarpine. Sweat is subsequently collected and analyzed to determine the chloride level. Chloride levels greater than 60 mmol/L in patients older than 6 months indicates the presence of the disease. Chloride levels up to 39 mmol/L are considered normal (Scott, 2013). In infants younger than 6 months sweat chloride levels less than 30 mmol/L are considered normal. One percent of patients with unusual genotypes of cystic fibrosis have normal sweat chloride concentrations. After a genetic test has been conducted and the result shows 2 CFTR mutations a second sweat test has to be conducted to confirm presence of cystic fibrosis in these patients. Other diagnostic tests should be employed in case sweat chloride tests are inconclusive. Nasal potential difference should therefore be performed (Scott, 2013). Other tests to be done incase of inconclusive sweat chloride tests should be the CT of the chest and the sinuses, bronchoscopy with bronchial lavage to culture bacteria, in the lower airway, pancreatic imaging, and ultrasonography of the vas deferens in male patients. Some modern neonatal screening tests can be done to help in proactive treatment of cystic fibrosis (Scott, 2013). This kind of test helps in preventing symptoms...
Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.
Get Started Now